Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700

Journal of Clinical Oncology

Volumn 25, Issue 13, 2007, Pages 1665-1669

  Isacoff, William H ^a   Bendetti, Jacqueline K ^a   Barstis, John J ^a   Jazieh, Abdul Rahman ^a   Macdonald, John S ^a   Philip, Philip A ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPYRIDAMOLE; FLUOROURACIL; FOLINIC ACID; MITOMYCIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT OBSTRUCTION; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE PERFORATION; LUNG FIBROSIS; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; STOMATITIS; TREATMENT RESPONSE; VOMITING; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIPYRIDAMOLE; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 34249100896     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.7637     Document Type: Article

References (25)

1. Jemal A, Thomas A, Murray T, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
2. Wasshaw AL, Fernandez-del Castillo C: Medical progress: Pancreatic carcinoma. N Engl J Med 326:455-465, 1992
3. Blackstock AW, Cox AD, Tepper JE: Treatment of pancreatic cancer: Current limitations, future possibilities. Oncology 10:301-307, 1996
4. Moertel CG, Frytak S, Hahn RG, et al: Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate-dose radiation (4000 Rads + 5-flourouracil), and high-dose radiation + 5-flourouracil - The Gastrointestinal Tumor Study Group. Cancer 48:1705-1710, 1981
5. Klassen DJ, MacIntyre JM, Catton GE, et al: Treatment of locally advanced unresectable cancer of the stomach and pancreas: A randomized comparison of 5-flourouracil alone with radiation plus concurrent and maintenance 5-flourouracil - An Eastern Cooperative Oncology Group Study. J Clin Oncol 3:373-377, 1985
6. The Gastrointestinal Tumor Study Group: Radiation therapy combined with Adriamycin or 5-flourouracil for the treatment of locally unresectable pancreatic carcinoma. Cancer 56:2563-2568, 1985
7. Phase II studies of drug combinations in advanced pancreatic carcinoma: Fluorouracil plus doxorubicin plus mitomycin-C and two regimens of streptozocin plus mitomycin-C plus fluorouracil. J Clin Oncol 4:1794-1798, 1986
8. The Gastrointestinal Tumor Study Group: Treatment of locally advanced unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone: The Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80:1751-1755, 1988
9. Storniolo AM, Enas MH, Brown CA, et al: An investigational new drug treatment program with gemcitabine: Results for over 3000 patients with pancreatic carcinoma. Cancer 85:1261-1268, 1999
10. Grem JL: 5-Fluorouracil plus leucovorin in cancer therapy. In De Vita VT, Hellman S, Rosenberg SA (eds): Principles and Practice of Oncology, Vol 2 (ed 2). Philadelphia, PA, JP Lippincott, 1988, pp 1-13
11. Chabner BA (ed): Pyrimidine Antagonists in Pharmacologic Principles of Cancer Treatment. Philadelphia, PA, WB Saunders, 1982, pp 183-212
12. Aschele C, Sobrero A, Faderan MA, et al: Novel mechanisms of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992
13. Sobrero FA, Aschele C, Bertino JR: Fluorouracil in colorectal cancer: A tale of two drugs - implications for biochemical modulation. J Clin Oncol 15:368-381, 1997
14. Grothey A, Descher B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU) folinic acid (FA) (MAYO) vs. weekly high dose 5-FU infusion/FA plus oxaliplatin (OXA) (FU FOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 21:129a, 2002 (suppl; abstr 512)
15. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
16. Van Mouwerik TJ, Pangallo CA, Willson JK, et al: Augmentation of methotrexate cytotoxicity in human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem Pharmacol 36:809-814, 1987
17. Grem JL: Biochemical modulation of fluorouracil by dipyridamole: Principal and clinical experience. Semin Oncol 19:56-65, 1992
18. Russello O, Romanini A, Civallen S, et al: Time-dependent interactions between 5-fluorouracil and mitomycin-C on a human colon carcinoma cell line, HCT-8 in vitro. Eur J Cancer Clin Oncol 25:571-572, 1989
19. Ross P, Cunningham D, Webb A, et al: A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin-C in advanced colorectal cancer. Ann Oncol 8:995-1001, 1997
20. Isacoff WH, Jacobs AD, Tylor O: Continuous infusion (CI) fluorouracil (5-FU) combined with calcium leucovorin, mitocycin-C (MMC), and dipyridomile (D) in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 10:154, 1991
21. Todd KE, Gloor B, Lane JS, et al: Resection of locally advanced pancreatic cancer after down-staging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin and dipyridamole. J Gastrointest Surg 2:159-166, 1998
22. Tsai Ty, Innitti DA, Safran H: Combined modality therapy for pancreatic cancer. Semin Oncol 30:71-79, 2003
23. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
24. Hoffman JP, Lipsitz S, Pisansky T: Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group Study. J Clin Oncol 16:317-323, 1998
25. Kamthan AG, Morris JC, Dalton T, et al: Combined modality therapy for stage II and stage III pancreatic cancer. J Clin Oncol 15:2920-2927, 1997